DDInter1335 DDInter1840
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) CCNA2
CCNA2 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) STAP2
STAP2 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) NR4A1
NR4A1 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) DAG1
DAG1 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) EZH2
EZH2 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) MPZL1
MPZL1 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Bosutinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Pazopanib {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Omacetaxine mepesuccinate (Compound) downregulates CCNA2 (Gene) and CCNA2 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Omacetaxine mepesuccinate (Compound) upregulates STAP2 (Gene) and STAP2 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Omacetaxine mepesuccinate (Compound) upregulates NR4A1 (Gene) and NR4A1 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Omacetaxine mepesuccinate (Compound) downregulates DAG1 (Gene) and DAG1 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Omacetaxine mepesuccinate (Compound) upregulates EZH2 (Gene) and EZH2 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Omacetaxine mepesuccinate (Compound) downregulates MPZL1 (Gene) and MPZL1 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)